title: Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
abstract: BACKGROUND
  In neuroblastoma (NB), the presence of segmental chromosome alterations (SCAs) is associated with a higher risk of relapse.
  
  
  METHODS
  In order to analyse the role of SCAs in infants with localised unresectable/disseminated NB without MYCN amplification, we have performed an array CGH analysis of tumours from infants enrolled in the prospective European INES trials.
  
  
  RESULTS
  Tumour samples from 218 out of 300 enroled patients could be analysed. Segmental chromosome alterations were observed in 11%, 20% and 59% of infants enroled in trials INES99.1 (localised unresectable NB), INES99.2 (stage 4s) and INES99.3 (stage 4) (P<0.0001). Progression-free survival was poorer in patients whose tumours harboured SCA, in the whole population and in trials INES99.1 and INES99.2, in the absence of clinical symptoms (log-rank test, P=0.0001, P=0.04 and P=0.0003, respectively). In multivariate analysis, a SCA genomic profile was the strongest predictor of poorer progression-free survival.
  
  
  CONCLUSIONS
  In infants with stage 4s MYCN-non-amplified NB, a SCA genomic profile identifies patients who will require upfront treatment even in the absence of other clinical indication for therapy, whereas in infants with localised unresectable NB, a genomic profile characterised by the absence of SCA identifies patients in whom treatment reduction might be possible. These findings will be implemented in a future international trial.
authors.affiliation: INSERM U830, Laboratoire de Génétique et Biologie des Cancers, 26 rue d'Ulm, Paris Cedex 05, France. gudrun.schleiermacher@curie.net
authors.forename: G
authors.initials: G
authors.lastname: Schleiermacher
authors.forename: J
authors.initials: J
authors.lastname: Michon
authors.forename: A
authors.initials: A
authors.lastname: Ribeiro
authors.forename: G
authors.initials: G
authors.lastname: Pierron
authors.forename: V
authors.initials: V
authors.lastname: Mosseri
authors.forename: H
authors.initials: H
authors.lastname: Rubie
authors.forename: C
authors.initials: C
authors.lastname: Munzer
authors.forename: J
authors.initials: J
authors.lastname: Bénard
authors.forename: N
authors.initials: N
authors.lastname: Auger
authors.forename: V
authors.initials: V
authors.lastname: Combaret
authors.forename: I
authors.initials: I
authors.lastname: Janoueix-Lerosey
authors.forename: A
authors.initials: A
authors.lastname: Pearson
authors.forename: D A
authors.initials: DA
authors.lastname: Tweddle
authors.forename: N
authors.initials: N
authors.lastname: Bown
authors.forename: M
authors.initials: M
authors.lastname: Gerrard
authors.forename: K
authors.initials: K
authors.lastname: Wheeler
authors.forename: R
authors.initials: R
authors.lastname: Noguera
authors.forename: E
authors.initials: E
authors.lastname: Villamon
authors.forename: A
authors.initials: A
authors.lastname: Cañete
authors.forename: V
authors.initials: V
authors.lastname: Castel
authors.forename: B
authors.initials: B
authors.lastname: Marques
authors.forename: A
authors.initials: A
authors.lastname: de Lacerda
authors.forename: G P
authors.initials: GP
authors.lastname: Tonini
authors.forename: K
authors.initials: K
authors.lastname: Mazzocco
authors.forename: R
authors.initials: R
authors.lastname: Defferrari
authors.forename: B
authors.initials: B
authors.lastname: de Bernardi
authors.forename: A
authors.initials: A
authors.lastname: di Cataldo
authors.forename: N
authors.initials: N
authors.lastname: van Roy
authors.forename: B
authors.initials: B
authors.lastname: Brichard
authors.forename: R
authors.initials: R
authors.lastname: Ladenstein
authors.forename: I
authors.initials: I
authors.lastname: Ambros
authors.forename: P
authors.initials: P
authors.lastname: Ambros
authors.forename: K
authors.initials: K
authors.lastname: Beiske
authors.forename: O
authors.initials: O
authors.lastname: Delattre
authors.forename: J
authors.initials: J
authors.lastname: Couturier
mesh_terms: D002869:Chromosome Aberrations; D006801:Humans; D007223:Infant; D000071447:N-Myc Proto-Oncogene Protein; D009447:Neuroblastoma / Q000235:genetics / Q000473:pathology*; D009687:Nuclear Proteins / Q000235:genetics*; D015513:Oncogene Proteins / Q000235:genetics*; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D016019:Survival Analysis
chemical_list: C459801:MYCN protein, human; D000071447:N-Myc Proto-Oncogene Protein; D009687:Nuclear Proteins; D015513:Oncogene Proteins